Hepatitis C virus in patients on regular hemodialysis in Beni-Suef Governorate, Egypt

Senosy, Shaimaa; Shabrawy, Ekram M. El

doi:10.1097/01.epx.0000484091.57255.c0

Cited by 13 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results are agreement with a previous studies have reported in Iraq [26], and in Iran [27]. But they were disagreement with the other study in Egypt [28]. Also, there were not significant differences (p >0.05) between sex and anti-HCV positive in the study, this similar to another previously reported study [29].…”

Section: Discussionsupporting

confidence: 72%

Assessment of Hepatitis C virus (HCV) associated with hemodialysis patients in Thi-Qar province, Iraq

Khalaf¹,

Hussein²

2022

Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9

View full text Add to dashboard Cite

Hepatitis is liver inflammation that can lead to many fatal health problems. Hepatitis C virus (HCV) is a blood-borne virus. Hemodialysis patients are at greater risk of acquiring HCV infection and this is a major global health problem. The study included 120 samples from patients who underwent dialysis at the age range of 20 to 87 years; males were 58.3% while 41.7% were females. The study confirmed that the percentage of HCV infection among Hemodialysis patients was 30%, the high rate was in age groups 50-59 years (33.3 %), in males is high than females. There was an association between blood transfusion and HCV infection (P value=0.037). Also, the high percentage was in patients who remained more than 36 months 50.0% and twice sessions per week at 61.1%. Six isolates were recorded in the global GenBank with accession numbers: MW947494-MW947499. History of blood transfusions and a long period of Hemodialysis treatment were major risk factors for anti-HCV positive. HCV RNA testing should be conducted on all patients prior to Hemodialysis and blood before transfusion using PCR.

show abstract

Section: Discussionsupporting

confidence: 72%

Assessment of Hepatitis C virus (HCV) associated with hemodialysis patients in Thi-Qar province, Iraq

Khalaf¹,

Hussein²

2022

Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9

View full text Add to dashboard Cite

show abstract

“…The minimum prevalence was 0.8% (Libya) [ 25 ] and 2.3% (Nigeria) [ 23 ] for HBV and HCV, respectively. On the other hand, the maximum prevalence of HBV and HCV was 60.7% (Egypt) [ 59 ] and 60.9% (Egypt) [ 43 ], respectively. A total of 23 studies reported the prevalence of HBV in HD patients.…”

Section: Resultsmentioning

confidence: 99%

The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis

Adane

Getawa

2021

PLoS ONE

View full text Add to dashboard Cite

Background Due to its invasive procedure patients on hemodialysis (HD) are at high risk of infections. Infections acquired in dialysis units can prolong hospitalization date and/or prolong illness in patients, and increase treatment cost. There are no adequate data on the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections in HD patients. Therefore, this study aimed to estimate the pooled prevalence and associated factors of HBV and HCV infections among HD patients in Africa. Method The databases PubMed, Medline, EMBASE, Cochrane library, web of science, African Journals Online, Science Direct, and Google Scholar were searched to identify relevant studies. The review was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were extracted independently by two authors and analyzed using STATA 11. A random-effect model was fitted to estimate the pooled prevalence with their 95% confidence interval. To detect publication bias funnel plots analysis and Egger weighted regression tests were done. Results The overall pooled prevalence of HBV and HCV infection among HD patients in Africa was 9.88% (95% CI: 7.20–12.56) I2 = 97.9% and 23.04% (95% CI: 18.51–2757) I2 = 99.6%, respectively. In addition, the pooled prevalence of HBV and HCV co-infection was 7.18% (95% CI: 3.15–11.20) I2 = 99.6%. Duration of dialysis was found to be the contributing factor for the occurrence of HBV and HCV among HD patients (OR = 1.44; 95% CI: 1.04, 2.01). Conclusion This study showed that there is high prevalence of HBV and HCV infections in HD patients in Africa. Therefore, strict adherence to precautions of infection control measures, isolation of seropositive patients, improvement in infrastructures, adequate screening of HBV and HCV for the donated blood, and decentralized HD services is needed to minimize the risk of HBV and HCV infections in HD facilities.

show abstract

“…Plusieurs études, s'étaient intéressées à sa prévalence en hémodialyse, et cette dernière diffère selon les pays et les centres d'hémodialyse. Senosy SA et al [15] rapportaient une prévalence de 60,9% dans un centre de dialyse en Egypte, tans disque Hasanjani R et al [16], en Iran, rapportaient dans leur etude une prévalence à 8,7% de patients infectés par le VHC. Cette prévalence de l'infection par le VHC parmi nos populations dialysées constitue une véritable menace de santé publique, car en plus de sa transmission par voie sanguine, il se transmet également par voie sexuelle.…”

Section: Discussionunclassified

Gestion de l’Anémie des patients hémodialysés chroniques : cas du Service de Néphrologie et d’hémodialyse du CHU du Point G au Mali

Tounkara¹,

Coulibaly²,

Coulibaly³

et al. 2017

Pan Afr Med J

View full text Add to dashboard Cite

IntroductionL'anémie est une complication fréquente de l'IRC couramment retrouvée chez les patients hémodialysés chroniques. Chez ces derniers, la prise en charge est principalement basée sur l'administration d'érythropoïétine et la supplémentation en fer. Le but de ce travail était d'évaluer la prise en charge de l'anémie des hémodialysés chroniques dans le service de Néphrologie du CHU du Point G.MéthodesIl s'agissait d'une étude transversale réalisée dans ledit service du 1er au 31 Août 2016.RésultatsAu total, 63 patients sur 174 participants avaient été retenus, 34 hommes et 29 femmes avec un sex-ratio à 1,17 en faveur des hommes. L'âge moyen des patients était de 48,79 ans ± 11,59, la durée moyenne en hémodialyse était de 3,77ans ± 2,6. La fréquence hospitalière de l'anémie chez nos dialysés était de 84,12%. La transfusion sanguine était retrouvée chez 92,1%, avec une moyenne annuelle de 5,81poches ± 5,91. La supplémentation martiale était notée dans 87,3% des cas. Les moyennes respectives de ferritine et de CST étaient de 1245 ng/ml ± 629,52 et 46,16%±19,12. L'administration occasionnelle d'EPO à des doses n'excédant pas les 4000UI était rapportée par 79,4% des patients. La principale difficulté pour l'utilisation de l' EPO était le coût (74,6%). L'infection au VHC touchait 60,1% des patients ayant réalisé le dit bilan.ConclusionLa gestion de l'anémie des dialysés chroniques doit être intégrée dans un cadre politique nationale de la santé.

show abstract

Hepatitis C virus in patients on regular hemodialysis in Beni-Suef Governorate, Egypt

Abstract: HCV infection still remains a predominant problem among patients on maintenance HD in Beni- Suef governorate History of blood transfusion and history of shistosomiasis were significant risk factors for acquiring HCV infection in these patients.

Cited by 13 publications

References 14 publications

Assessment of Hepatitis C virus (HCV) associated with hemodialysis patients in Thi-Qar province, Iraq

Assessment of Hepatitis C virus (HCV) associated with hemodialysis patients in Thi-Qar province, Iraq

The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis

Gestion de l’Anémie des patients hémodialysés chroniques : cas du Service de Néphrologie et d’hémodialyse du CHU du Point G au Mali

Contact Info

Product

Resources

About